2021至2024年欧洲六家中毒中心报告的娱乐性药物中毒
该研究汇总了奥地利、弗莱堡(德国)、荷兰、瑞典、瑞士和英国六家中毒中心2021至2024年的回顾性数据,纳入11种娱乐性药物相关中毒病例。四年间六中心共记录1,051,287例中毒,其中23,779例(2.3%)涉及娱乐性药物;娱乐性药物暴露占比从2021年的1.8%(n=4,581)升至2024年的2.6%(n=7,229),主要由奥地利、弗莱堡和英国的增长驱动。δ-9-四氢大麻酚、可卡因、安非他明和3,4-亚甲二氧基甲基安非他明最常涉及,且各国有明显差异。作者认为协调的欧洲监测可能支持及时的公共卫生干预和预防策略。
要点
- 2021至2024年六家欧洲中毒中心娱乐性药物中毒占全部中毒的2.3%(23,779/1,051,287),占比从2021年1.8%(n=4,581)升至2024年2.6%(n=7,229)。
- 增长主要来自奥地利、弗莱堡(德国)和英国;2021年各中心率从1.3%(奥地利)到2.8%(荷兰),2024年从1.9%(奥地利)到3.6%(弗莱堡)。
- 最常涉及的药物为δ-9-四氢大麻酚、可卡因、安非他明和3,4-亚甲二氧基甲基安非他明。
- 率上升的药物包括δ-9-四氢大麻酚(弗莱堡、奥地利)、可卡因(弗莱堡、英国)、安非他明(弗莱堡、瑞典)和氯胺酮(奥地利、弗莱堡、英国)。
- 2024年安非他明中毒率在弗莱堡(0.63%)和瑞典(0.94%)达峰,可卡因在弗莱堡(0.78%)和英国(0.74%)达峰,氯胺酮在荷兰(0.42%)和英国(0.24%)达峰。
适用人群与场景
- 2021至2024年向奥地利、弗莱堡(德国)、荷兰、瑞典、瑞士和英国六家中毒中心报告的、涉及11种娱乐性药物(安非他明、可卡因、δ-9-四氢大麻酚、γ-羟丁酸、海洛因、氯胺酮、麦角酸二乙酰胺、3,4-亚甲二氧基甲基安非他明、甲基安非他明、poppers和裸盖菇素)的中毒病例。
研究设计与关键结果
- 回顾性汇总数据分析:2021至2024年六家欧洲中毒中心共记录1,051,287例中毒,其中23,779例(2.3%)涉及娱乐性药物。
- 娱乐性药物暴露率从2021年1.8%(n=4,581)升至2024年2.6%(n=7,229),主要驱动来自奥地利、弗莱堡和英国。
- 各中心率范围:2021年从1.3%(奥地利)到2.8%(荷兰),2024年从1.9%(奥地利)到3.6%(弗莱堡)。
- 最常涉及的药物为δ-9-四氢大麻酚、可卡因、安非他明和3,4-亚甲二氧基甲基安非他明。
- 率上升的药物:δ-9-四氢大麻酚(弗莱堡、奥地利)、可卡因(弗莱堡、英国)、安非他明(弗莱堡、瑞典)、氯胺酮(奥地利、弗莱堡、英国)。
- 2024年峰值:安非他明在弗莱堡0.63%、瑞典0.94%;可卡因在弗莱堡0.78%、英国0.74%;氯胺酮在荷兰0.42%、英国0.24%。
证据类型、等级与局限
- 证据类型:基于六家欧洲中毒中心2021至2024年汇总数据的回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,娱乐性药物中毒虽仅占中毒中心呼叫的约3%,但2021至2024年显著增加,凸显中毒中心在毒物监测和早期识别新兴药物趋势中的价值。
- 作者认为,协调的欧洲娱乐性药物中毒监测可能支持及时的公共卫生干预和预防策略。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Recreational drug poisonings pose a growing public health concern. European-level data remain limited, although poison centres are well placed to monitor related health incidents. This study analysed temporal trends in recreational drug poisonings reported to six European poison centres.
METHODS: Aggregated retrospective data were collected over four years (2021-2024) from poison centres in Austria, Freiburg (Germany), the Netherlands, Sweden, Switzerland, and the United Kingdom. Cases involving 11 recreational drugs (amfetamine, cocaine, delta-9-tetrahydrocannabinol, gamma-hydr-oxybutyrate, heroin, ketamine, lysergic acid diethylamide, 3,4-methylenedioxymetamfetamine, metamfetamine, poppers, and psilocybin) were included. Annual rates of recreational drug exposures were calculated relative to all poisoned patients, and trends were analysed using linear regression.
RESULTS: From 2021 to 2024, the six centres recorded 1,051,287 poisonings, of which 23,779 (2.3%) involved recreational drugs. The rate of recreational drug exposures increased from 1.8% (n = 4,581) in 2021 to 2.6% (n = 7,229) in 2024, mainly driven by the increases in Austria, Freiburg, and the United Kingdom. Rates ranged from 1.3% (Austria) to 2.8% (Netherlands) in 2021 and from 1.9% (Austria) to 3.6% (Freiburg) in 2024. Delta-9-tetrahydrocannabinol, cocaine, amfetamine, and 3,4-methylenedioxymetamfetamine were most frequently implicated. Increasing rates were observed for delta-9-tetrahydrocannabinol (Freiburg, Austria), cocaine (Freiburg, United Kingdom), amfetamine (Freiburg, Sweden), and ketamine (Austria, Freiburg, United Kingdom). In 2024, amfetamine poisonings peaked in Freiburg (0.63%) and Sweden (0.94%), cocaine in Freiburg (0.78%) and the United Kingdom (0.74%), and ketamine in the Netherlands (0.42%) and the United Kingdom (0.24%).
DISCUSSION: Although recreational drug poisonings comprised a small proportion of poison centre calls (∼3%), a significant increase was observed between 2021 and 2024, underscoring their value in toxicovigilance and early identification of emerging drug trends.
CONCLUSIONS: Delta-9-tetrahydrocannabinol, cocaine, amfetamine, and 3,4-methylenedioxymetamfetamine were most frequently reported, with notable national differences. Coordinated European monitoring of recreational drug poisonings may support timely public health interventions and prevention strategies.
参考来源
- Hondebrink L, Faber K, Kader A, et al. Recreational drug poisonings reported to six European poison centres from 2021 to 2024. Clin Toxicol (Phila). 2026. PMID: 41778415. doi:10.1080/15563650.2026.2628073
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。